2016
Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model
Siefert AL, Ehrlich A, Corral MJ, Goldsmith-Pestana K, McMahon-Pratt D, Fahmy TM. Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model. Biomaterials 2016, 108: 168-176. PMID: 27636154, PMCID: PMC5049880, DOI: 10.1016/j.biomaterials.2016.09.004.Peer-Reviewed Original ResearchConceptsPathogen-associated molecular patternsAccumulation of MDSCsHyper-inflammatory responseOngoing immune responseCytokine IL-10Antigen-presenting cellsCurrent treatment strategiesInflammation-mediated diseasesLong treatment regimensSite of infectionNew World leishmaniasisCellular immunomodulationIL-17Suppressor cellsDendritic cellsIL-10Immunotherapeutic approachesChronic inflammationTreatment regimensIL-13Free CpGTreatment strategiesTherapeutic effectImmune responsePreclinical studies
2015
Cutaneous leishmaniasis is regulated by Wnt antagonist Dkk-1 from activated platelets (MPF7P.715)
Bothwell A, Chae W, Ehrlich A, Teixeira A, Goldsmith-Pestana K, Maher S, Hwa J, Krause D, McMahon-Pratt D. Cutaneous leishmaniasis is regulated by Wnt antagonist Dkk-1 from activated platelets (MPF7P.715). The Journal Of Immunology 2015, 194: 203.16-203.16. DOI: 10.4049/jimmunol.194.supp.203.16.Peer-Reviewed Original ResearchNeutrophil-platelet aggregate formationDkk-1Cutaneous leishmaniasisLate inflammatory responseSkin inflammatory diseasesT cell differentiationMajor infectionAntigen exposureLymph nodesChronic inflammationTh2 cytokinesInflammatory diseasesInflammatory responseTh2 cellsSkin lesionsSmall molecule inhibitorsParasite burdenGATA-3Functional inhibitionMarked inhibitionLeishmaniasisC-MafHuman plateletsMolecule inhibitorsPlatelets